Latest Articles
Adding Olaparib (Lynparza) to Durvalumab (Imfinzi) Shows Benefit in Endometrial Cancer Subgroups - OBR Oncology
Adding Olaparib (Lynparza) to Durvalumab (Imfinzi) Shows Benefit in Endometrial Cancer Subgroups OBR Oncology
Published: March 18, 2025, 10:24 a.m.
Adding Olaparib (Lynparza) to Durvalumab (Imfinzi) Shows Benefit in Endometrial Cancer Subgroups - Oncology News Central
Adding Olaparib (Lynparza) to Durvalumab (Imfinzi) Shows Benefit in Endometrial Cancer Subgroups Oncology News Central
Published: March 18, 2025, 10:24 a.m.
Adding Olaparib (Lynparza) to Durvalumab (Imfinzi) Shows Benefit in Endometrial Cancer Subgroups - oncologynewscentral.com
Adding Olaparib (Lynparza) to Durvalumab (Imfinzi) Shows Benefit in Endometrial Cancer Subgroups oncologynewscentral.com
Published: March 18, 2025, 10:24 a.m.
(PDF) Association Between Hepatic Steatosis Index and Endometrial Cancer Risk: A Cross-Sectional Study - ResearchGate
(PDF) Association Between Hepatic Steatosis Index and Endometrial Cancer Risk: A Cross-Sectional Study ResearchGate
Published: March 18, 2025, 5:59 a.m.
Lenvatinib plus pembrolizumab not associated with improved survival compared to standard therapy for recurrent endometrial cancer - 2 Minute Medicine
Lenvatinib plus pembrolizumab not associated with improved survival compared to standard therapy for recurrent endometrial cancer 2 Minute Medicine
Published: March 17, 2025, 11:07 p.m.
Real-World Analysis Confirms Efficacy/Safety of Dostarlimab Plus Chemotherapy in Advanced Endometrial Cancer - OncLive
Real-World Analysis Confirms Efficacy/Safety of Dostarlimab Plus Chemotherapy in Advanced Endometrial Cancer OncLive
Published: March 17, 2025, 9:22 p.m.
AI diagnoses endometrial cancer with near perfect accuracy - Medical Xpress
AI diagnoses endometrial cancer with near perfect accuracy Medical Xpress
Published: March 17, 2025, 8:16 p.m.
Dostarlimab/Chemo Improves Long-Term DOR in Advanced Endometrial Cancer - OncLive
Dostarlimab/Chemo Improves Long-Term DOR in Advanced Endometrial Cancer OncLive
Published: March 17, 2025, 6:19 p.m.
Dr Westin on PFS Benefit With DUO-E Regimen Across Histologic and Molecular pMMR Endometrial Cancer Subgroups - OncLive
Dr Westin on PFS Benefit With DUO-E Regimen Across Histologic and Molecular pMMR Endometrial Cancer Subgroups OncLive
Published: March 17, 2025, 5:39 p.m.
Advances in Endometrial Cancer Detection, Treatment - The ASCO Post
Advances in Endometrial Cancer Detection, Treatment The ASCO Post
Published: March 17, 2025, 3:48 p.m.
Link copied to clipboard!